Epidermolysis Bullosa – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Epidermolysis Bullosa – Drugs In Development, 2024 report and make more profitable business decisions.
Epidermolysis bullosa (EB) is a group of inherited bullous disorders characterized by blister formation in response to mechanical trauma. Symptoms include blistering of skin; deformity or loss of fingernails and toenails; internal blistering including on the throat, esophagus, upper airway, stomach, intestines, and urinary tract; skin thickening on palms and soles of the feet (hyperkeratosis); and scalp blistering, scarring, and hair loss (scarring alopecia). Treatment includes antibiotics and surgery.
The Epidermolysis Bullosa drugs in development market research report provide comprehensive information on the therapeutics under development for Epidermolysis Bullosa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epidermolysis Bullosa and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Epidermolysis Bullosa | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 52 molecules, with 50 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Epidermolysis Bullosa therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Epidermolysis Bullosa pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Epidermolysis Bullosa treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Abeona Therapeutics IncAbregen Pty Ltd
Aegle Therapeutics Corp
Almirall SA
Amniotics AB
Amryt AG
Anterogen Co Ltd
Apteeus SAS
Avicanna Inc
Beijing Puqi Pharmaceutical Technology Co Ltd
Biomendics LLC
BPGbio Inc
Branca Bunus Ltd
Carocell Bio Ltd
Castle Creek Biosciences Inc
Celularity Inc
Centro de Investigaciones Biologicas
Chiesi Farmaceutici SpA
Constant Therapeutics LLC
CSA Biotechnologies LLC
Daewoong Pharmaceutical Co Ltd
Eloxx Pharmaceuticals Inc
Energenesis Biomedical Co Ltd
GeCell Therapeutics LLC
Holostem Terapie Avanzate SRL
Immusoft Corp
In2cure AB
InMed Pharmaceuticals Inc
Ishin Pharmaceuticals
Kangstem Biotech Co Ltd
Krystal Biotech Inc
LambdaGen Therapeutics
Mariposa Therapeutics Ltd
Onconova Therapeutics Inc
OTR3 SAS
Panag Pharma Inc
Paradigm Therapeutics Inc
Phoenicis Therapeutics Inc
Phoenix Tissue Repair Inc
Relief Therapeutics Holding AG
RHEACELL GmbH & Co KG
Shanghai Gencells Therapeutics Co Ltd
Shionogi & Co Ltd
StemRIM Inc
Tampere University of Technology
Telaria
Therapicon Srl
Winhealth Pharma
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Epidermolysis Bullosa reports